Prostate Cancer Clinical Trial

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Summary

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with respect to 1) radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR) and 2) overall survival (OS).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male participants with histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
Has metastatic disease assessed by investigator and verified by BICR by either ≥2 bone lesions on bone scan and/or visceral disease by computed tomography/magnetic resonance imaging (CT/MRI)
Willing to maintain continuous ADT with a LHRH agonists or antagonists during study treatment or have a history of bilateral orchiectomy
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 10 days of randomization
Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization
Has adequate organ function
Has provided newly obtained core or excisional biopsy (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed). Participants with bone only or bone predominant disease may provide a bone biopsy sample
Male participants must agree to the following during the intervention period and for at least 120 days after the last dose of study intervention: Refrain from donating sperm PLUS either be abstinent from heterosexual intercourse and agree to remain abstinent OR agree to use contraception, unless confirmed to be azoospermic
Male participants must agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person of any sex

Exclusion Criteria:

Has a known additional malignancy that is progressing or has required active treatment in the last 3 years
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
Has undergone major surgery including local prostate intervention (excluding prostate biopsy) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications
Has a gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules
Has an active infection (including tuberculosis) requiring systemic therapy
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has known active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Has known or suspected central nervous system (CNS) metastases and/or carcinomatous meningitis
Has a history of seizure or any condition that may predispose to seizure
Has a history of loss of consciousness within 12 months of screening
Has had myocardial infarction or uncontrolled angina within 6 months prior to randomization, or has New York Heart Association class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure
Has hypotension (systolic blood pressure <86 millimeters of mercury [mmHg]) or uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg) at the screening visit
Has a history of clinically significant ventricular arrhythmias
Has hypersensitivity to pembrolizumab and/or enzalutamide and/or any of their excipients
Has received prior ADT as neoadjuvant/adjuvant therapy for non-metastatic prostate cancer for >39 months in duration or within 9 months prior to randomization or with evidence of disease progression while receiving ADT
Has had prior treatment with a next generation hormonal agent (eg, abiraterone, enzalutamide, apalutamide, darolutamide)
Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
Has received a live vaccine within 30 days prior to randomization
Has a "superscan" bone scan
Has had an allogenic tissue/solid organ transplant
Is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment

Has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer with the following exceptions:

Up to 3 months of ADT or orchiectomy with or without concurrent first-generation antiandrogens, if patient was not treated with docetaxel
May have 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic disease if it was administered at least 4 weeks prior to randomization
For participants with low volume metastatic disease, may have 1 course of definitive radiotherapy if it was administered at least 4 weeks prior to randomization
Up to 6 cycles of docetaxel therapy with final treatment administration completed within 2 months of randomization and no evidence of disease progression. In these participants up to 6 months of ADT permitted

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

1232

Study ID:

NCT04191096

Recruitment Status:

Active, not recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 213 Locations for this study

See Locations Near You

Alaska Clinical Research Center ( Site 0274)
Anchorage Alaska, 99503, United States
Providence Alaska Medical Center ( Site 0276)
Anchorage Alaska, 99508, United States
City of Hope Medical Center ( Site 0217)
Duarte California, 91010, United States
UCLA Hematology/Oncology - Santa Monica ( Site 0241)
Los Angeles California, 90404, United States
University of Colorado, Anschutz Cancer Pavilion ( Site 0236)
Aurora Colorado, 80045, United States
Hartford HealthCare Medical Group ( Site 0212)
Manchester Connecticut, 06042, United States
Smilow Cancer Center at Yale-New Haven ( Site 0250)
New Haven Connecticut, 06510, United States
Sibley Memorial Hospital ( Site 0275)
Washington District of Columbia, 20016, United States
Winship Cancer Institute of Emory University ( Site 0209)
Atlanta Georgia, 30322, United States
The University of Chicago ( Site 0264)
Chicago Illinois, 60637, United States
Springfield Clinic [Springfield, IL] ( Site 0240)
Springfield Illinois, 62702, United States
Cotton-O'Neil Cancer Center ( Site 0228)
Topeka Kansas, 66606, United States
The Sidney Kimmel Comprehensive Cancer Center ( Site 0204)
Baltimore Maryland, 21287, United States
St. Vincent Frontier Cancer Center-Research ( Site 0213)
Billings Montana, 59102, United States
Comprehensive Cancer Centers of Nevada ( Site 0269)
Las Vegas Nevada, 89169, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0270)
New York New York, 10016, United States
Weill Cornell Medical College ( Site 0263)
New York New York, 10065, United States
Associated Medical Professionals of NY ( Site 0251)
Syracuse New York, 13210, United States
Duke University ( Site 0206)
Durham North Carolina, 27710, United States
Tri-State Urologic Services PSC, Inc. ( Site 0253)
Cincinnati Ohio, 45212, United States
MidLantic Urology ( Site 0273)
Bala-Cynwyd Pennsylvania, 19004, United States
Ralph H. Johnson VA Center ( Site 0256)
Charleston South Carolina, 29401, United States
Carolina Urologic Research Center ( Site 0259)
Myrtle Beach South Carolina, 29572, United States
Urology Associates [Nashville, TN] ( Site 0233)
Nashville Tennessee, 37209, United States
Inova Health System ( Site 0205)
Fairfax Virginia, 22031, United States
Urology of Virginia ( Site 0224)
Virginia Beach Virginia, 23462, United States
Seattle Cancer Care Alliance ( Site 0258)
Seattle Washington, 98109, United States
Chris OBrien Lifehouse ( Site 0300)
Camperdown New South Wales, 2050, Australia
Port Macquarie Base Hospital ( Site 0301)
Port Macquarie New South Wales, 2444, Australia
Riverina Cancer Care Center ( Site 0302)
Wagga Wagga New South Wales, 2650, Australia
Gallipoli Medical Research Foundation ( Site 0309)
Greenslopes Queensland, 4120, Australia
John Flynn Hospital & Medical Centre ( Site 0308)
Tugun Queensland, 4224, Australia
Box Hill Hospital ( Site 0304)
Box Hill Victoria, 3128, Australia
Monash Health ( Site 0305)
Clayton Victoria, 3168, Australia
Peter MacCallum Cancer Centre ( Site 0306)
Melbourne Victoria, 3000, Australia
Fiona Stanley Hospital ( Site 0311)
Murdoch Western Australia, 6150, Australia
Ordensklinikum Linz GmbH Elisabethinen ( Site 0901)
Linz Oberosterreich, 4020, Austria
Landeskrankenhaus Salzburg - Universitatklinikum der PMU ( Site 0900)
Salzburg , 5020, Austria
Krankenhaus der Barmherzigen Brüder Wien ( Site 0904)
Wien , 1020, Austria
Medizinische Universitaet Wien ( Site 0903)
Wien , 1090, Austria
Oncocentro Ceara ( Site 2309)
Fortaleza Ceara, 60135, Brazil
Instituto de Cancer e Transplante de Curitiba ICTR ( Site 2306)
Curitiba Parana, 80510, Brazil
Hospital Sao Vicente de Paulo ( Site 2303)
Passo Fundo Rio Grande Do Sul, 99010, Brazil
Hospital de Clinicas de Porto Alegre ( Site 2304)
Porto Alegre Rio Grande Do Sul, 90035, Brazil
Clinica de Oncologia Reichow ( Site 2308)
Blumenau Santa Catarina, 89010, Brazil
Fundacao Dr Amaral Carvalho ( Site 2302)
Jau Sao Paulo, 17210, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 2305)
Sao Paulo , 01246, Brazil
The Ottawa Hospital ( Site 0100)
Ottawa Ontario, K1H 8, Canada
Niagara Health System - St. Catharines ( Site 0107)
St. Catharines Ontario, L2S 0, Canada
CISSS de la Monteregie-Centre ( Site 0105)
Greenfield Park Quebec, J4V 2, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0109)
Montreal Quebec, H2X 3, Canada
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0106)
Montreal Quebec, H3T 1, Canada
CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0101)
Quebec , G1R 2, Canada
Centro Investigación del Cáncer James Lind ( Site 2401)
Temuco Araucania, 47800, Chile
IC La Serena Research ( Site 2406)
La Serena Coquimbo, 17204, Chile
Clinica Universidad Catolica del Maule ( Site 2407)
Talca Maule, 34655, Chile
Clinica Alemana ( Site 2408)
Santiago Region M. De Santiago, 76505, Chile
Pontificia Universidad Catolica de Chile ( Site 2402)
Santiago Region M. De Santiago, 83300, Chile
Sociedad Medica Aren y Bachero Limitada ( Site 2403)
Santiago Region M. De Santiago, 84203, Chile
Oncocentro ( Site 2400)
Vina del Mar Valparaiso, 25205, Chile
Peking University First Hospital ( Site 0800)
Beijing Beijing, 10003, China
Zhejiang Provincial People's Hospital ( Site 0809)
Hangzhou Zhejiang, 31001, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 0834)
Wenzhou Zhejiang, 32500, China
Institucion Prestadora de Servicios de Salud Clinica de la Costa LTDA ( Site 2504)
Barranquilla Atlantico, 08002, Colombia
Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2509)
Valledupar Cesar, 20000, Colombia
Administradora Country SA - Clinica del Country ( Site 2507)
Bogota Distrito Capital De Bogota, 11022, Colombia
Instituto Nacional de Cancerologia E.S.E ( Site 2506)
Bogota Distrito Capital De Bogota, 11032, Colombia
Hemato Oncologos ( Site 2503)
Cali Valle Del Cauca, 76004, Colombia
Rigshospitalet ( Site 1005)
Copenhagen Hovedstaden, 2100, Denmark
Herlev og Gentofte Hospital. ( Site 1004)
Herlev Hovedstaden, 2730, Denmark
Aalborg Universitetshospital ( Site 1000)
Aalborg Nordjylland, 9000, Denmark
Odense Universitetshospital ( Site 1003)
Odense Syddanmark, 5000, Denmark
Vejle Sygehus ( Site 1002)
Vejle Syddanmark, 7100, Denmark
Keski-Suomen keskussairaala ( Site 1017)
Jyvaskyla Mellersta Finland, 40620, Finland
Tampereen yliopistollinen sairaala ( Site 1022)
Tampere Pirkanmaa, 33520, Finland
HYKS ( Site 1020)
Helsinki Varsinais-Suomi, 00290, Finland
TYKS T-sairaala Syopatautien pkl ( Site 1019)
Turku Varsinais-Suomi, 20521, Finland
Centre Leon-Berard ( Site 1110)
Lyon Auvergne, 69373, France
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1114)
Strasbourg Bas-Rhin, 67200, France
CHU de Brest -Site Hopital Morvan ( Site 1103)
Brest Bretagne, 29200, France
Centre Georges Francois Leclerc ( Site 1112)
Dijon Cote-d Or, 21079, France
CHU-Jean Minjoz ( Site 1101)
Besancon Doubs, 25000, France
Institut Bergonie ( Site 1104)
Bordeaux Gironde, 33076, France
Hopital Foch ( Site 1105)
Suresnes Hauts-de-Seine, 92151, France
C.H.R.U. de Rennes. Hopital de Pontchaillou ( Site 1117)
Rennes Ille-et-Vilaine, 35033, France
Institut Jean Godinot-Clinical Research Unit ( Site 1118)
Reims Marne, 51726, France
Centre D Oncologie de Gentilly ( Site 1107)
Nancy Meurthe-et-Moselle, 54100, France
Centre Bourgogne ( Site 1119)
Lille Nord-Pas-de-Calais, 59000, France
Hospices Civils de Lyon Centre Hospitalier Lyon Sud ( Site 1102)
Pierre Benite Rhone, 69310, France
Hopital Henri Mondor ( Site 1116)
Creteil Val-de-Marne, 94010, France
Universitaetsklinikum Freiburg ( Site 1200)
Freiburg Baden-Wurttemberg, 79106, Germany
Klinikum der Universitaet Muenchen - Grosshadern ( Site 1210)
Muenchen Bayern, 81377, Germany
Klinikum Rechts der Isar ( Site 1206)
Munchen Bayern, 81675, Germany
Klinikum Nuernberg Nord ( Site 1213)
Nurnberg Bayern, 90419, Germany
Staedtisches Klinikum Braunschweig gGmbH ( Site 1217)
Braunschweig Niedersachsen, 38126, Germany
Universitaetsklinikum Magdeburg A.o.R. ( Site 1211)
Magdeburg Sachsen-Anhalt, 39120, Germany
Universitaetsklinikum der Technischen Universitaet Dresden ( Site 1204)
Dresden Sachsen, 01307, Germany
Charite Universitaetsmedizin Berlin ( Site 1201)
Berlin , 10117, Germany
Universitaetsklinikum Hamburg-Eppendorf ( Site 1212)
Hamburg , 20246, Germany
Cork University Hospital ( Site 1304)
Cork , T12 D, Ireland
Beaumont Hospital ( Site 1302)
Dublin , 00009, Ireland
Tallaght University Hospital ( Site 1301)
Dublin , D24 N, Ireland
St Vincents University Hospital ( Site 1300)
Dublin , DO4 Y, Ireland
University Hospital Limerick ( Site 1305)
Limerick , V94 F, Ireland
University Hospital Waterford ( Site 1303)
Waterford , X91 E, Ireland
Rambam Medical Center ( Site 1400)
Haifa , 31096, Israel
Hadassah Ein Kerem Medical Center ( Site 1404)
Jerusalem , 91120, Israel
Meir Medical Center ( Site 1401)
Kfar Saba , 44281, Israel
Rabin Medical Center ( Site 1402)
Petach Tikva , 49414, Israel
Sourasky Medical Center ( Site 1403)
Tel Aviv , 64239, Israel
Assaf Harofeh Medical Center ( Site 1405)
Zerifin , 70300, Israel
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1503)
Meldola Emilia-Romagna, 47014, Italy
Istituto Clinico Humanitas Research Hospital ( Site 1500)
Rozzano Lombardia, 20089, Italy
Centro Di Riferimento Oncologico ( Site 1511)
Aviano Pordenone, 33081, Italy
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 1509)
Bari , 70124, Italy
Azienda Ospedaliera Cannizzaro ( Site 1501)
Catania , 95126, Italy
Istituto Nazionale dei Tumori ( Site 1510)
Milano , 20133, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1508)
Napoli , 80131, Italy
Fondazione Policlinico Universitario A. Gemelli ( Site 1512)
Roma , 00168, Italy
Azienda Ospedaliera Santa Maria ( Site 1502)
Terni , 05100, Italy
A.O. Verona-Ospedale Civile Maggiore Borgo-Trento ( Site 1504)
Verona , 37126, Italy
Toho University Sakura Medical Center ( Site 0732)
Sakura Chiba, 285-8, Japan
Ehime University Hospital ( Site 0745)
Toon Ehime, 791-0, Japan
Sapporo Medical University Hospital ( Site 0730)
Sapporo Hokkaido, 060-8, Japan
Kitasato University Hospital ( Site 0734)
Sagamihara Kanagawa, 252-0, Japan
Yokohama City University Medical Center ( Site 0735)
Yokohama Kanagawa, 232-0, Japan
Nara Medical University Hospital ( Site 0744)
Kashihara Nara, 634-8, Japan
Kindai University Hospital ( Site 0743)
Osakasayama Osaka, 589-8, Japan
Osaka University Hospital ( Site 0742)
Suita Osaka, 565-0, Japan
Saitama Medical University International Medical Center ( Site 0737)
Hidaka Saitama, 350-1, Japan
Dokkyo Medical University Saitama Medical Center ( Site 0736)
Koshigaya Saitama, 343-8, Japan
Hamamatsu University Hospital ( Site 0748)
Hamamatsu Shizuoka, 431-3, Japan
Yamaguchi University Hospital ( Site 0746)
Ube Yamaguchi, 755-8, Japan
Chiba Cancer Center ( Site 0733)
Chiba , 260-8, Japan
Harasanshin Hospital ( Site 0747)
Fukuoka , 812-0, Japan
Nagano Municipal Hospital ( Site 0731)
Nagano , 381-8, Japan
Osaka City University Hospital ( Site 0741)
Osaka , 545-8, Japan
Toranomon Hospital ( Site 0740)
Tokyo , 105-8, Japan
Nippon Medical School Hospital ( Site 0738)
Tokyo , 113-8, Japan
Tokyo Women's Medical University Hospital ( Site 0739)
Tokyo , 162-8, Japan
Chonnam National University Hwasun Hospital ( Site 0406)
Jeollanam-do Jeonranamdo, 58128, Korea, Republic of
National Cancer Center ( Site 0400)
Gyeonggi-do Kyonggi-do, 10408, Korea, Republic of
Seoul National University Bundang Hospital ( Site 0401)
Seongnam-si Kyonggi-do, 13620, Korea, Republic of
Kyungpook National University Chilgok Hospital ( Site 0404)
Daegu Taegu-Kwangyokshi, 41404, Korea, Republic of
Seoul National University Hospital ( Site 0405)
Seoul , 03080, Korea, Republic of
Severance Hospital Yonsei University Health System ( Site 0402)
Seoul , 03722, Korea, Republic of
Asan Medical Center ( Site 0403)
Seoul , 05505, Korea, Republic of
Hospital San Lucas Cardiologica del Sureste ( Site 2606)
Tuxtla Gutierrez Chiapas, 29090, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 2607)
Guadalajara Jalisco, 44280, Mexico
Centro Estatal de Cancerologia de Chihuahua ( Site 2608)
Chihuahua , 31000, Mexico
Grupo Medico Camino SC ( Site 2613)
Mexico City , 03310, Mexico
Centro Oncologico Internacional. SEDNA ( Site 2609)
Mexico City , 04700, Mexico
Boca Raton Clinical Research QTO ( Site 2611)
Queretaro , 76070, Mexico
Radboud University Medical Center ( Site 1606)
Nijmegen Gelderland, 6500 , Netherlands
Antoni van Leeuwenhoek Ziekenhuis ( Site 1603)
Amsterdam Noord-Holland, 1066 , Netherlands
Vrije Universiteit Medisch Centrum ( Site 1601)
Amsterdam Noord-Holland, 1081 , Netherlands
Isala Klinieken, Locatie Sophia ( Site 1604)
Zwolle Overijssel, 8025 , Netherlands
Meander Medisch Centrum ( Site 1602)
Amersfoort Utrecht, 3813 , Netherlands
Franciscus Gasthuis en Vlietland ( Site 1605)
Schiedam Zuid-Holland, 3118 , Netherlands
St. Antonius Ziekenhuis ( Site 1600)
Utrecht , 3543 , Netherlands
Auckland City Hospital ( Site 0321)
Auckland , 1023, New Zealand
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 2700)
Arequipa Ariqipa, 04001, Peru
Clinica Peruano Americana S.A. ( Site 2702)
Trujillo La Libertad, 13011, Peru
Hospital Nacional Guillermo Almenara Irigoyen ( Site 2708)
Lima , 15033, Peru
Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 2706)
Lima , 15036, Peru
Hospital Militar Central [Lima, Peru] ( Site 2704)
Lima , 15076, Peru
Szpital Uniwersytecki nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy ( Site 1720)
Bydgoszcz Kujawsko-pomorskie, 85-09, Poland
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1716)
Bydgoszcz Kujawsko-pomorskie, 85-79, Poland
Nasz Lekarz Przychodnie Medyczne ( Site 1718)
Torun Kujawsko-pomorskie, 87-10, Poland
Szpital Uniwersytecki w Krakowie ( Site 1707)
Krakow Malopolskie, 30-68, Poland
Radomskie Centrum Onkologii ( Site 1701)
Radom Mazowieckie, 26-60, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1700)
Przemysl Podkarpackie, 37-70, Poland
Wojewodzki Szpital Specjalistyczny nr 4 w Bytomiu ( Site 1717)
Bytom Slaskie, 41-90, Poland
Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu Medycznego im. K. Marcinkowskiego w Pozna
Poznan Wielkopolskie, 61-84, Poland
Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1709)
Koszalin Zachodniopomorskie, 75-58, Poland
Twoja Przychodnia - Szczeciskie Centrum Medyczne ( Site 1721)
Szczecin Zachodniopomorskie, 71-43, Poland
Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 1810)
Krasnoyarsk Krasnoyarskiy Kray, 66013, Russian Federation
SBIH City clinical hospital named after D.D. Pletniov ( Site 1813)
Moscow Moskva, 10507, Russian Federation
Russian Scientific Center of Roentgenoradiology ( Site 1800)
Moscow Moskva, 11799, Russian Federation
Volga District Medical Center Federal Medical and Biological Agency ( Site 1805)
Nizhny Novgorod Nizhegorodskaya Oblast, 60307, Russian Federation
Omsk Clinical Oncology Dispensary ( Site 1809)
Omsk Omskaya Oblast, 64401, Russian Federation
Instituto Catalan de Oncologia - ICO ( Site 1901)
Hospitalet de Llobregat Barcelona, 08908, Spain
Hospital Josep Trueta ( Site 1900)
Girona Gerona, 17007, Spain
Hospital Universitario Lucus Augusti ( Site 1905)
Lugo , 27003, Spain
Hospital Universitario Ramon y Cajal ( Site 1902)
Madrid , 28034, Spain
Hospital Clinico San Carlos ( Site 1906)
Madrid , 28040, Spain
Hospital 12 de Octubre de Madrid ( Site 1903)
Madrid , 28041, Spain
Hospital Virgen de la Macarena ( Site 1904)
Sevilla , 41071, Spain
Kantonsspital Graubuenden ( Site 2003)
Chur Grisons, 7000, Switzerland
Kantonsspital St. Gallen ( Site 2000)
St. Gallen Sankt Gallen, 9007, Switzerland
CHUV (centre hospitalier universitaire vaudois) ( Site 2002)
Lausanne Vaud, 1011, Switzerland
Universitaetsspital Zuerich ( Site 2001)
Zuerich Zurich, 8091, Switzerland
Kaohsiung Chang Gung Memorial Hospital ( Site 0504)
Kaohsiung , 83301, Taiwan
National Cheng Kung University Hospital ( Site 0503)
Tainan , 70457, Taiwan
National Taiwan University Hospital ( Site 0500)
Taipei , 100, Taiwan
Taipei Veterans General Hospital ( Site 0501)
Taipei , 11217, Taiwan
Chang Gung Medical Foundation. Linkou ( Site 0502)
Taoyuan , 333, Taiwan
Chulalongkorn Hospital, Medical Oncology Unit ( Site 0600)
Bangkok Krung Thep Maha Nakhon, 10330, Thailand
Ramathibodi Hospital. ( Site 0601)
Bangkok Krung Thep Maha Nakhon, 10400, Thailand
Faculty of Medicine Siriraj Hospital ( Site 0602)
Bangkok Krung Thep Maha Nakhon, 10700, Thailand
Srinagarind Hospital ( Site 0604)
Khon Kaen , 40002, Thailand
Acibadem Adana Hastanesi ( Site 2106)
Adana , 01130, Turkey
Ankara Universitesi Tip Fakultesi. ( Site 2101)
Ankara , 06100, Turkey
Hacettepe Universitesi Tıp Fakultesi ( Site 2105)
Ankara , 06230, Turkey
Ankara Sehir Hastanesi ( Site 2103)
Ankara , 06800, Turkey
Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 2100)
Istanbul , 34098, Turkey
Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 2102)
Izmir , 35100, Turkey
Konya Necmettin Erbakan University Medical Faculty ( Site 2104)
Konya , 42080, Turkey
Aberdeen Royal Infirmary ( Site 1315)
Aberdeen Aberdeen City, AB25 , United Kingdom
Royal Cornwall Hospitals NHS Trust ( Site 1317)
Truro Cornwall, TR1 3, United Kingdom
University College London Hospitals NHS Foundation Trust ( Site 1320)
London London, City Of, NW1 2, United Kingdom
Royal Marsden NHS Foundation Trust ( Site 1318)
London London, City Of, SW3 6, United Kingdom
Velindre Cancer Centre Hospital ( Site 1322)
Cardiff , CF14 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

1232

Study ID:

NCT04191096

Recruitment Status:

Active, not recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.